Conference Day One
8:25 am Check-In & Light Breakfast
8:55 am Chair’s Opening Remarks
Creating Easy-to-Scale Projects to Become an Attractive Acquisition Prospect for Investors
9:00 am Navigating Investment Pathways for Startup Companies Within the Nasal Space
Synopsis
- Emphasis on presenting strong preclinical and early clinical data that demonstrate the safety, efficacy, and unique benefits of the intranasal drug, showcasing its potential for market success
- Discussion of the importance of articulating a compelling value proposition that outlines the product’s competitive advantages, potential market impact, and alignment with current healthcare trends
- Insights into building strategic partnerships with industry leaders and highlighting any existing funding or collaborations that enhance credibility
9:30 am Roundtable: Exploring Strategies Employed From Starting a Drug Company to Successful Exit
Synopsis
- Overview of key initial steps in building a nasal drug company, including identifying niche markets, developing a unique value proposition, and securing initial funding
- Effective strategies for navigating regulatory pathways and clinical trials specific to nasal drug delivery, ensuring compliance, and accelerating product development
- Crafting a strategic exit plan, including identifying potential acquirers, forming partnerships with larger pharmaceutical companies, and positioning the company for maximum valuation at exit
10:00 am Panel: Examining the Venture Capitalist Criteria for Intranasal Delivery Startup Investments
Synopsis
- How venture capitalists assess the market size, unmet needs, and competitive dynamics of the intranasal delivery sector to gauge the potential for growth and return on investment
- Insights into the importance of demonstrating unique technology, strong intellectual property, and innovative approaches in drug formulation and delivery that set the startup apart from competitors
- Emphasis on the necessity of having a capable management team with relevant experience and a clear, executable business plan, including regulatory pathways and commercialization strategies, to instill investor confidence
10:30 am Speed Networking
Synopsis
This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. Get face-to-face time with many of the nasal formulation and delivery experts to establish meaningful business relationships.
11:00 am Morning Break & Networking
11:30 am Demonstrating Value to Venture Capitalists to Secure Investment for Intranasal Drug Development
Synopsis
- Examine investor due diligence with patient advocacy
- Best practices for investors to understand the relationship between advocacy organizations and KOLs
- Understanding the role that these different groups play in the valuation of new products
12:00 pm Keep It Simple Stupid: Making Intranasal Biologic Drugs for Population Scale Access
Synopsis
- GMP scalability and COGS once made intranasal biologics impossible
- New technology makes this feasible today, unlocking key advantages in development costs, commercial viability, and equitable access
- How to think about optimally balancing the tradeoffs between safety, purity, and developability
12:30 pm Lunch & Networking
Increasing Drug Bioavailability in Target Regions to Maximize Drug Utility
1:30 pm Enhancing Bioavailability of Nasal Drugs to Maximise Drug Retention in the Brain
Synopsis
- Discussion of innovative formulation approaches designed to facilitate direct drug transport to the brain while minimizing systemic absorption into the bloodstream
- Examination of techniques to optimize the intranasal delivery route, including device design and administration protocols, to enhance localized drug retention
- Ways to assess the distribution of drugs in the brain versus systemic circulation, guiding formulation adjustments to improve overall bioavailability and therapeutic efficacy
2:00 pm Enhancing Bioavailability of Nasal Drugs to Maximize Drug Retention in Systemic Targets
Synopsis
- Increase bioavailability and retention for targeted efficacy
- Explore pathways to enhance systemic absorption
- Strategies to reduce nasal clearance for sustained drug impact
2:30 pm Afternoon Break & Networking
3:00 pm Roundtable: Exploring the Effects of Drugs on the Nasal Membranes Before Reaching the Target Region
Synopsis
- Analysis of how various excipients and formulation components influence the integrity and permeability of nasal membranes
- Discussion on the interactions between drugs and nasal mucosa, including potential irritation or toxicity
- Overview of methodologies, such as in vitro models and histological evaluations, used to study the effects of drugs on nasal membranes
3:30 pm Bridging Pre-Clinical & Early Human Studies With Clinical Design
Synopsis
- Case-study led insights on current clinical development program
- Design of clinical trials and how this is linked back to delivery
- Ways to optimize these methods